Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 233-241

  Patlolla, Ram R ^a   Chougule, Mahavir ^a   Patel, Apurva R ^a   Jackson, Tanise ^a   Tata, Prasad N V ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Celecoxib; Inhalation; Lung cancer; Lung disposition; Nanostructured lipid carrier

Indexed keywords

A549 CELLS; AERODYNAMIC PROPERTIES; AEROSOL PROPERTIES; AEROSOLIZATION; BALB/C MICE; CELECOXIB; ENTRAPMENT EFFICIENCY; HIGH PRESSURE HOMOGENIZATION; IN-VITRO; LUNG CANCER; LUNG TISSUE; MINIMAL DOSING; NANOSTRUCTURED LIPID CARRIERS; PATIENT COMPLIANCE; PHARMACOKINETIC PARAMETERS; TAUROCHOLATE; TIME DEPENDENT;

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; LEAD; NANOPARTICLES; SODIUM;

BIOLOGICAL ORGANS;

CELECOXIB; GLYCEROL BEHENATE; MIGLYOL; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

AEROSOLS; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; FEASIBILITY STUDIES; LIPIDS; LUNG; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; PYRAZOLES; SULFONAMIDES;

EID: 77952670687     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.006     Document Type: Article

References (41)

1. Walker J.E., Odden A.R., Jeyaseelan S., Zhang P., Bagby G.J., Nelson S., Happel K.I. Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication. Alcohol. Clin. Exp. Res. 2009, 33:357-365.
2. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
3. Hitzman C.J., Elmquist W.F., Wattenberg L.W., Wiedmann T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 2006, 95:1114-1126.
4. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of amiloride hydrochloride. J. Nanosci. Nanotechnol. 2006, 6:3001-3009.
5. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., DeLima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
6. Reddy P.R., Venkateswarlu V. Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. J. Drug Target. 2005, 13:543-553.
7. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
8. Muller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002, 242:121-128.
9. Pardeike A., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
10. Joshi M., Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm. 2008, 346(1-2):124-132.
11. Hida T., Kozaki K.I., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahasi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 2000, 6:2006-2011.
12. Shishodia S., Koul D., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J. Immunol. 2004, 173:2011-2022.
13. Mao J.T., Roth M.D., Serio K.J., Baratelli F., Zhu L., Holmes E.C., Strieter R.M., Dubinett S.M. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin. Cancer Res. 2003, 9:5835-5841.
14. Seedher N., Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003, 4:E33.
15. Haynes A., Shaik M.S., Chatterjee A., Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm. Res. 2005, 22:427-439.
16. Fulzele S.V., Chatterjee A., Shaik M.S., Jackson T., Singh M. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm. Res. 2006, 23:2094-2106.
17. Thakkar H., Sharma R.K., Murthy R.S.R. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D 2007, 8(5):275-285.
18. Patlolla R.R., Vobalaboina V. Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. J. Pharm. Sci. 2005, 94:437-445.
19. Xiang Q.Y., Wang M.T., Chen F., Gong T., Jian Y.L., Zhang Z.R., Huang Y. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch. Pharm. Res. 2007, 30(4):519-525.
20. Jackson T., Chougule M.B., Ichite N., Patlolla R.R., Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother. Pharmacol. 2008, 63:117-126.
21. Ichite N., Chougule M.B., Jackson T., Fulzele S.V., Safe S., Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin. Cancer Res. 2009, 15:543-552.
22. Cooney D., Kazantseva M., Hickey A.J. Development of a size-dependant aerosol deposition model utilizing airway epithelial cells for evaluating aerosol drug delivery. Altern to Labor Animals 2004, 32:581-590.
23. Kazantseva M., Cooney D., Hickey A.J. Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery. Respiratory Drug Delivery VIII 2002, 707-710. Davis Horwood International Publishing, Ltd., Raleigh, NC, USA. P.R. Byron, R.N. Dalby, J. Peart, S.J. Farr (Eds.).
24. Tan A., Simovic S., Davey K.A., Rades T., Prestidge A.C. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J. Control. Release 2009, 134:62-70.
25. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm. 2008, 357:295-304.
26. Yang W., Peters J.I., Williams R.O. Inhaled nanoparticles - a current review. Int. J. Pharm. 2008, 356:239-247.
27. Kasting G.B., Francis W.R., Bowman L.A., Kinnett G.O. Percutaneous absorption of vanilloids: in vivo and in vitro studies. J. Pharm. Sci. 1997, 86:142-146.
28. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 2004, 24:627-638.
29. Zhang L., Qian Y., Long C., Chen Y. Systematic procedures for formulation design of drug-loaded solid lipid microparticles: selection of carrier material and stabilizer. Ind. Eng. Chem. Res. 2004, 47:6091-6100.
30. Byron P.R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 1986, 75:433-438.
31. Singh M., Ferdous A.J., Jackson T.L. Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. J. Control. Release 1999, 59:43-53.
32. Schurch S., Gehr P., Im Hof V., Geiser M., Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir. Physiol. 1990, 80:17-32.
33. Lauweryns J.M., Baert J.H. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 1977, 115:625-683.
34. Sanna V., Kirschvink N., Gustin P., Gavini E., Roland I., Delattre L., Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 2004, 5:e27.
35. Muller R.H., Ruhl D., Runge A.S. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 1996, 144:115-121.
36. Byron P.R., Patton J.S. Drug delivery via the respiratory tract. J. Aerosol Med. 1994, 7:49-75.
37. Jaques P.A., Kim C.S. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal. Toxicol. 2000, 12:715-731.
38. Geiser M., Schurch S., Gehr P. Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J. Appl. Physiol. 2003, 94:1793-1801.
39. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1998, 1408:79-89.
40. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
41. Kobayashi S., Kondo S., Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 1996, 13:80-83.